Lakefront Biotherapeutics NV announced it repurchased 117,471 of its own shares between August 17 and August 21, 2026, under the repurchase program announced on June 9, 2026. The buybacks were executed via a discretionary mandate to an independent financial intermediary across Euronext Amsterdam, CBOE Europe, Turquoise, and Aquis venues, at an average price of €24.40 per share for a total consideration of €2,866,035.10. As of market close on August 21, 2026, Lakefront holds 1,033,528 of its own ordinary shares.
LAKEFRONT BIOTHERAPEUTICS NV Company repurchased shares under buyback program, signaling confidence and supporting stock price.
Pfizer Inc